BD-AcAc 2, usually added in diet and given orally, can elevate mean blood ketone bodies of 3.5 mm and lowered plasma glucose, insulin, and leptin in animals.

Miconazole Nitrate is a potent imidazole-based antifungal agent that is commonly used by topical administration to the skin or to mucous membranes to cure fungal infections. It works by inhibiting the synthesis of ergosterol, a critical component of fungal cell membranes. It can also be used against certain species of Leishmania protozoa which are a […]

PCI-27483 is a novel, potent and reversible small-molecule inhibitor of activated factor VII (factor VIIa) with potential anticancer and antithrombotic activities. Factor VII is a serine protease which can be activated (FVIIa) upon binding with TF forming the FVIIa/TF complex, which induces intracellular signaling pathways by activating protease activated receptor 2 (PAR-2). Upon subcutaneous administration, […]

NSC-41589 is a N-[2-(methylsulfanyl) phenyl]acetamide analog with bioactivities.

Dexrazoxane (formerly also known as ICRF-187; ADR-529; NSC-169780) is an intracellular iron chelator, which decreases the formation of superoxide radicals, and is mainly used as a cardioprotective agent. As a derivative of EDTA, dexrazoxane chelates iron, but the precise mechanism by which it protects the heart is not known. This agent is used to protect […]

U83836E is a novel and potent lipid peroxidation (LP) inhibitor. U-83836E prevents hydrogen peroxide-induced F2 isoprostane production in renal proximal tubular cells, prevents free radical mediated effects of oxyhemoglobin in vascular smooth muscle, and reduces secondary brain injury in a rabbit model of cryogenic trauma. Research shows that U-83836E improves survival of rat embryonic mesencephalic […]

Alclofenac, a drug of the non-steroidal anti-inflammatory drug (NSAIDs) class, has been used to treat patients with chronic rheumatic diseases but was withdrawn from the UK market in 1979 due to concerns with its association with vasculitis and rash. Alclofenac has a pronounced effect upon the acute-phase protein response and the extent to which L-tryptophan […]

GSK-3008348 (GSK3008348), an investigational drug, is a novel and potent integrin alpha(v)beta6 antagonist that is being developed by GlaxoSmithKline Research and Development Limited (the Sponsor, a pharmaceutical company based in the UK) for the treatment of Idiopathic Pulmonary Fibrosis (IPF). IPF is a rare and poorly understood disease that causes scarring of the lungs. The […]

SB-224289 hydrochloride is a novel, potent and selective 5-HT1B receptor antagonist with anxiolytic effect with pKi of 8.2. SB 224289 displays > 60-fold selectivity over 5-HT1D, 5-HT1A, 5-HT1E, 5-HT1F, 5-HT2A and 5-HT2C receptors in radioligand binding and functional assays. SB 224289 is a centrally active following oral administration in vivo.

SC-26196 is a novel, potent and orally bioactive D6D (Delta6 desaturase) inhibitor with IC50 of 0.2 µM in a rat liver microsomal assay. It completely blocks the conversion of linoleic acid to arachidonic acid (AA). SC-26196 inhibited the desaturation of 2 microM [1-14C] 18:2n-6 by 87-95% in cultured human skin fibroblasts, coronary artery smooth muscle […]